The Evolving Role of Chemotherapy for Hormone-Sensitive Prostate Cancer

Video

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

Clinical Pearls

Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the evolving role of chemotherapy for hormone-sensitive prostate cancer.

  • Oncologists have been trained in the use of chemotherapy — they are aware of the side effects.
  • The side effect profile of chemotherapy is essentially the same as when used for castration-resistant disease.
  • The question remains: Is there a difference in using docetaxel in the hormone-sensitive or castration-resistant settings?
  • The rate of neutropenic fever was slightly higher in the CHAARTED study (8%) compared with the TAX 327 study (3%).
Related Videos
Video 5 - "Addressing Unmet Needs and Final Perspectives on nmCRPC"
Video 4 - "Integrating ARAMIS Trial Data and Managing Adverse Events in nmCRPC Treatment"
Video 3 - "Optimizing Treatment, Biomarkers, and Chemotherapy for Patients with nmCRPC"
Video 2 - "Addressing Risks and Challenges in the Standard of Care for Patients with nmCRPC"
Video 1 - "Overview of a 75-Year-old Patient with Non-Metastatic Castration-Resistant Prostate Cancer’s Case"
Related Content